Literature DB >> 17342860

2006 drug approvals: finding the niche.

Joanna Owens.   

Abstract

Mesh：

Year:  2007        PMID： 17342860     DOI： 10.1038/nrd2247

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  11 in total

Review 1.  [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].

Authors:  R W C Janzen; W D Ludwig
Journal:  Z Rheumatol       Date:  2012-02       Impact factor: 1.372

2.  New paradigms for treatment development.

Authors:  Ellen L Stover; Linda Brady; Stephen R Marder
Journal:  Schizophr Bull       Date:  2007-08-02       Impact factor: 9.306

Review 3.  Microfluidics for drug discovery and development: from target selection to product lifecycle management.

Authors:  Lifeng Kang; Bong Geun Chung; Robert Langer; Ali Khademhosseini
Journal:  Drug Discov Today       Date:  2007-11-26       Impact factor: 7.851

4.  Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA Adverse Event Reporting System data.

Authors:  Pankdeep Chhabra; Xing Chen; Sheila R Weiss
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

5.  Heterotransplant mouse model cohorts of human malignancies: A novel platform for Systematic Preclinical Efficacy Evaluation of Drugs (SPEED).

Authors:  Ashutosh K Pathak; Manisha Bhutani; Pierre Saintigny; Li Mao
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

6.  Unraveling the autoimmune translational research process layer by layer.

Authors:  Richard S Blumberg; Bonnie Dittel; David Hafler; Matthias von Herrath; Frank O Nestle
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

7.  Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group.

Authors:  Fatma Al Jasmi; Mohammed Al Jumah; Fatimah Alqarni; Nouriya Al-Sanna'a; Fawziah Al-Sharif; Saeed Bohlega; Edward J Cupler; Waseem Fathalla; Mohamed A Hamdan; Nawal Makhseed; Shahriar Nafissi; Yalda Nilipour; Laila Selim; Nuri Shembesh; Rawda Sunbul; Seyed Hassan Tonekaboni
Journal:  BMC Neurol       Date:  2015-10-15       Impact factor: 2.474

Review 8.  Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact.

Authors:  Remco L A de Vrueh; Daan J A Crommelin
Journal:  Pharm Res       Date:  2017-06-06       Impact factor: 4.200

9.  Market failure and the poverty of new drugs in maternal health.

Authors:  Nicholas M Fisk; Rifat Atun
Journal:  PLoS Med       Date:  2008-01-22       Impact factor: 11.069

10.  Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal.

Authors:  Thomas A Faunce
Journal:  Aust New Zealand Health Policy       Date:  2007-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.